COVID-19 @ NIBIB

Covid-19 Banner

NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx® Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx® Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx®) Tech and ATP Programs

Mesa Biotech point of care COVID test

The RADx® Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

generic bar chart titled tests produced

Summary data on proposals submitted to the RADx® Tech and ATP Programs.

RADx Testing

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

three researchers in a lab

Listing of COVID-19 related grants funded by NIBIB.

MRI of chest with arrows pointing to points on the lungs

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about this resource.

Videos

View videos about RADx® Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADx® Tech/ATP programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech/ATP Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19NIBIB@nih.gov

Related Resources

NIH COVID-19 website

Learn about clinical trials for treatments and vaccines at HHS Combat COVID

NIH COVID-19 Information for Applicants/Grantees

Media Inquiries: nibibpress@mail.nih.gov or 301-496-3500

About COVID-19

Research information from NIH | Español

Public health information from CDC

NIH staff guidance on coronavirus (NIH Only)

Related News

View All News
New research shows value of at-home antigen tests in slowing spread of COVID-19
Grantee News
April 20, 2022
Two recent studies supported by the National Institutes of Health Rapid Acceleration of Diagnostics (RADx) Tech program demonstrate how widespread distribution of COVID-19 at-home antigen tests can be used as an effective public health strategy to reduce the spread of the disease. Source: UMass Chan
New saliva COVID-19 test receives Emergency Use Authorization from FDA
Grantee News
April 19, 2022
A new type of COVID-19 test is hitting the market, and could change how we detect the virus. MicroGEM, a Virginia-based molecular biology company with a Charlottesville office, is using its new saliva test to track COVID-19. Source: NBC TV12 Richmond, Virginia.
Nasal antiviral blocks SARS-CoV-2 infection in mice
NIBIB in the News
April 12, 2022
An NIH-funded team at Cornell University has developed a compound delivered into the nose that blocked a protein used by SARS-CoV-2 to get into cells and prevented severe infection in mice. Antiviral drugs that target host cells may work against many existing and future variants of the virus that causes COVID-19. Source: NIH Research Matters
Blood test may indicate higher risk pregnancies in patients with COVID-19
Grantee News
March 17, 2022
A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The finding builds on another study with similar results and could have implications in how physicians screen for and address high-risk pregnancies.
New rapid PCR COVID test receives FDA emergency use authorization
Grantee News
March 16, 2022
A new rapid PCR COVID-19 test invented by Northwestern University faculty and Minute Molecular Diagnostics has received FDA emergency use authorization.